Abstract
Regeneron and Sanofi posted disappointing results from a Phase II trial testing their arthritis drug Kevzara in people hospitalized with COVID-19. Kevzara is an antibody that binds and blocks the IL-6 receptor. Although the drug lowered IL-6 levels, an action that may slow immune system flaring in COVID-19, the companies found no benefit compared with a placebo. A Phase III trial of the drug will be amended to include only critical patients and will administer only a high dose of Kevzara or a placebo.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
